We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

THE BINDING SITE

Engages in the research, development, manufacture, and distribution of immunodiagnostic assays, as wel as specialized... read more Featured Products: More products

Download Mobile App





Binding Site Showcases Optilite System for Special Protein Testing

By LabMedica International staff writers
Posted on 22 May 2023
Print article
Image: Optilite special protein analyzer on display at EuroMedLab Rome 2023 (Photo courtesy of Binding Site)
Image: Optilite special protein analyzer on display at EuroMedLab Rome 2023 (Photo courtesy of Binding Site)

Binding Site (Birmingham, UK) is showcasing its Optilite system, the leading solution for multiple myeloma and immune status testing, at the 2023 EuroMedLab Congress.

Optilite represents a significant breakthrough in special protein testing. The innovative system has been fully optimized to simplify complex analytical processes, delivering unparalleled efficiency, workflow optimization, and confidence in test results. With an array of intelligent features, Optilite sets a new standard in the protein laboratory field by seamlessly integrating cutting-edge technology and advanced software.

At EuroMedLab Rome 2023, Binding Site is also presenting its range of in vitro assays, which have received the CE mark for Europe, FDA clearance for the USA, and approval from regulatory authorities in multiple countries. These comprehensive assays cover all five isotypes of immunoglobulins, offering a complete solution. Among the assays being highlighted by Binding Site at the industry event are Freelite and Hevylite, which provide a comprehensive monitoring solution for managing patients with multiple myeloma.

The Freelite assay has significantly enhanced laboratory and clinical practices in the detection and follow-up of monoclonal gammopathies. The Optilite Freelite assay, FDA-cleared for aiding in the diagnosis and monitoring of multiple myeloma, represents the state-of-the-art in free light chain testing. Additionally, Hevylite is a unique immunoassay panel designed to accurately identify and quantify immunoglobulin heavy and light chain isotypes. Together, these advancements by Binding Site contribute to the advancement of diagnostic and monitoring capabilities in the field of multiple myeloma.

Related Links:
Binding Site 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Molecular Diagnostics

view channel
Image: The test can find tRNA fragments unique to Parkinson’s disease before patients even have symptoms (Photo courtesy of Shutterstock)

Rapid Blood Test Identifies Pre-Symptomatic Patients with Parkinson’s Disease

Currently, no reliable blood test exists for diagnosing Parkinson’s disease. Instead, physicians rely on observing a patient's movements, but this qualitative method has an error rate of 20%-25% and can... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.